Oncosil Medical Limited (ASX: OSL) - Share Price
Current share price for OSL : $0.570 0.02 (3.39%)+
OncoSil Medical (OSL), an ASX-listed company, is a global medical device company focused on Interventional Oncology and focuses on improving the outcomes for people living with cancer by utilizing the selected and targeted intratumoural placement of Phosphorous-32 (32P) Microparticles in addition to chemotherapy.
OSL General Information +
| ASX Code | OSL |
| Website | http://www.oncosil.com |
| Industry/Sector | Life Sciences Tools & Services |
| Market Cap ($M) | 17 |
| OSL Share Price | $0.570 |
| Day High | $0.590 |
| Day Low | $0.570 |
| Last Close | $0.590 |
| OSL Share Price Movement | $0.02 ( 3.39% ) |
Prices as at 16:40, 16 Jun 2026
+Security prices are delayed by at least 20 minutes and are indicative only.
Oncosil Medical Limited (OSL) Upcoming Dividends & Yields
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|
See all dividends from Oncosil Medical Limited (OSL) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
Oncosil Medical Limited (OSL) price-sensitive announcements
OSL - OncoSil progresses HDE with US FDA
OncoSil Medical Limited announced that the U.S. FDA has confirmed all outstanding question
Oncosil Medical Limited (OSL)
9 Jun 2026 | 9:48 AM
9 Jun 2026 | 9:48 AM
OSL - TRIPP-FFX Clinical Trial Meets Co-Primary Endpoints
OncoSil Medical Limited announced that their TRIPP-FFX clinical trial has successfully met
Oncosil Medical Limited (OSL)
9 Jun 2026 | 9:47 AM
9 Jun 2026 | 9:47 AM
OSL - Trading Halt
OncoSil Medical Ltd (OSL) has requested a trading halt on the ASX pending the release of a
Oncosil Medical Limited (OSL)
4 Jun 2026 | 9:09 AM
4 Jun 2026 | 9:09 AM
OSL - OncoSil Medical Receives TGA Approval in Australia
OncoSil Medical Limited, an Australian medical device company, has received approval from
Oncosil Medical Limited (OSL)
20 May 2026 | 9:17 AM
20 May 2026 | 9:17 AM
Oncosil Medical Limited (OSL) Recent ASX Announcements
OSL Financial Summary
| Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2025A | -$15.10 | -$137.40 | -38.10% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2024A | -$12.38 | -$221.80 | -41.20% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2023A | -$11.34 | -$377.20 | -6.60% | 0.00 | 0.00 | 0.00% | 0.0% |
OSL Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | ||
| Oncosil Medical Limited (OSL) | $18M | -0.3805 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
OSL Market Comparison
| Earnings | P/E Ratio | P/B Ratio | P/E Growth | |
|---|---|---|---|---|
| Company | 0.00 | 0.00 | 2.63 | 0.00 |
| Market | 0.30 | 13.20 | 1.18 | 0.68 |
| Sector | 0.40 | 27.30 | 2.51 | 2.19 |
OSL Directors
| Name | Position | Start Date |
|---|---|---|
| Mr Nigel Lange | Chief Executive Officer, Managing Director | 21 Jan 2021 |
| Mr Peter James MacDonald Hall | Non-Executive Director | 1 Oct 2024 |
| Ms Lelde Smits | Non-Executive Director | 15 Jan 2025 |
| Dr Thomas (Tom) Duthy | Non-Executive Director, Non-Executive Chairman | 11 Jul 2025 |
Oncosil Medical Limited (OSL) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 17 Mar 2026 | SMITS, Lelde | Issued | Indirect Shares | 44,120 | $0.680 | $30,001.600 |
| 17 Mar 2026 | DUTHY, Thomas (Tom) | Issued | Indirect Shares | 50,537 | $0.680 | $34,365.160 |
| 19 Jun 2025 | SMITS, Lelde | Issued | Options | 7,500 | $12.000 | $90,000.000 |
See all changes in directors' interest & trades for Oncosil Medical Limited (OSL) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
OSL Management
| Name | Position |
|---|---|
| Mr Douglas Cubbin | Chairman |
| Nova Taylor | Joint Company Secretary |
| Tim Luscombe | Joint Company Secretary |
OSL Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Oncosil Medical Limited (OSL). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 3,422,619 (18.18%) | Washington H. Soul Pattinson and Company Limited |
| 1,304,473 (6.93%) | State Street Australia Ltd |
OSL Calendar of Events
| Date | Event |
|---|---|
| 23 February 2027 | Report (Interim) |
| 22 October 2026 | Report (Annual) |
| 28 August 2026 | Report (Annual) |
| 28 August 2026 | Report (Prelim) |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
